Notes
human epidermal growth factor receptor-2
2020 US dollars
Reference
Moriwaki K, et al. Economic Evaluation of First-Line Pertuzumab Therapy in Patients with HER2-Positive Metastatic Breast Cancer in Japan. PharmacoEconomics-Open : 23 Jan 2021. Available from: URL: https://doi.org/10.1007/s41669-020-00254-3
Rights and permissions
About this article
Cite this article
First-line pertuzumab combination therapy not cost effective for BC. PharmacoEcon Outcomes News 871, 17 (2021). https://doi.org/10.1007/s40274-021-7455-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7455-z